Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H39N3O3 |
| Molecular Weight | 465.6276 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@@H](CN1CC[C@](C)([C@@H](C)C1)C2=CC(O)=CC=C2)NC(=O)[C@H]3CC4=C(CN3)C=C(O)C=C4
InChI
InChIKey=ZLVXBBHTMQJRSX-VMGNSXQWSA-N
InChI=1S/C28H39N3O3/c1-18(2)26(30-27(34)25-13-20-8-9-24(33)12-21(20)15-29-25)17-31-11-10-28(4,19(3)16-31)22-6-5-7-23(32)14-22/h5-9,12,14,18-19,25-26,29,32-33H,10-11,13,15-17H2,1-4H3,(H,30,34)/t19-,25+,26+,28+/m0/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT01431586?term=JDTIC&rank=1
Curator's Comment: description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT01431586?term=JDTIC&rank=1
JDTic demonstrated high affinity for the kappa opioid receptor in the binding assay and highly potent and selective kappa antagonism in the [(35)S]GTP-gamma-S assay. This drug was in phase I of clinical trials for the treatment of cocaine abuse, but development was stopped because of incidence of non-sustained ventricular tachycardia.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. | 2001 Aug 16 |
|
| Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist. | 2003 Jul 3 |
|
| Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist. | 2004 Oct 6 |
|
| Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. | 2005 Nov |
|
| Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. | 2007 Dec |
|
| Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. | 2007 Oct 12 |
|
| In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously. | 2007 Oct 13 |
|
| [11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging. | 2008 Jul |
|
| Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). | 2008 Mar 27 |
|
| Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). | 2009 Dec 10 |
|
| Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity. | 2010 Jul 22 |
|
| Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. | 2010 Jun |
|
| Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats. | 2010 Jun |
|
| Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. | 2010 Jun |
|
| Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse. | 2010 Jun |
Patents
Sample Use Guides
In Vitro Use Guide
Curator's Comment: JDTic demonstrated high affinity for the κ receptor in the binding assay and highly potent and selective κ antagonism in the [35S]GTP-γ-S assay. In the [35S]GTP-γ-S functional assay, JDTic demonstrated a 3.4-fold increase in κ antagonist potency relative to the functional assay utilizing guinea pig membranes.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
361444-66-8
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | |||
|
JDTIC
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | This study has been terminated.(No further subjects will be enrolled due to adverse events.) | ||
|
3C6FZ6UXC8
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | |||
|
DTXSID70433301
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | |||
|
9956146
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | |||
|
JDTIC
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | JDTic is a selective, long-acting ("inactivating") antagonist of the .KAPPA.-opioid receptor (KOR). JDTic is a 4-phenylpiperidine derivative, distantly related structurally to analgesics such as pethidine and ketobemidone, and more closely to the MOR antagonist alvimopan. In addition, it is structurally distinct from other KOR antagonists such as norbinaltorphimine. | ||
|
JDTIC
Created by
admin on Sat Dec 16 01:49:12 GMT 2023 , Edited by admin on Sat Dec 16 01:49:12 GMT 2023
|
PRIMARY | Kappa Antagonist JDTic in Phase 1 Clinical Trial |
ACTIVE MOIETY
